---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-015456"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:05:45.815574+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech prioritizes triple combo for HPV+ HNSCC; 75% 36-mo survival in Ph2

## Summary
- Three-year OS of 75% and 75% ORR in ICI-naive advanced HNSCC with PDS01ADC + Versamune HPV + KEYTRUDA.
- ICI-resistant group: 72% 12-month OS and 63% ORR at optimal PDS01ADC dose; median OS ~20 months.
- Full-year 2023 net loss $42.9M ($1.39/sh) vs $40.9M ($1.43/sh) in 2022; cash $56.6M at Dec 31.
- Company raised ~$10.5M net via ATM in Q4 2023 and appointed new CMO and CFO in late 2023/early 2024.
- VERSATILE-003 trial deprioritized; potentially pivotal randomized trial of triple combo expected to start in 2024.

## SEC filing metadata
- accession: 0001140361-24-015456
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/0001140361-24-015456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/ef20025224_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-015456
- JSON: https://secwatch.observer/filing/0001140361-24-015456.json
- Plain text: https://secwatch.observer/filing/0001140361-24-015456.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, EPS $1.39 per basic and diluted share.
  - Period: the year ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share
  - EPS: $1.39 per basic and diluted share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, compared to a net loss of $40.9 million, or $1.43 per basic share and diluted share, for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/0001140361-24-015456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.